Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features

Bibliographic Details
Title: Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
Authors: Jonathan D. Schoenfeld, Mizuki Nishino, Mariano Severgnini, Michael Manos, Raymond H. Mak, F. Stephen Hodi
Source: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Publisher Information: BMJ Publishing Group, 2019.
Publication Year: 2019
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Pneumonitis, Radiation., PD-1 inhibition., Biomarkers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Background Pneumonitis is a potential consequence of both lung-directed radiation and immune checkpoint blockade (ICB), particularly treatment with PD-1/PD-L1 inhibitors. Significant morbidity and mortality can result, and severe pneumonitis attributed to ICB precludes continued therapy. Thus, discriminating between radiation- and ICB- related pneumonitis is of importance for the increasing number of patients receiving both treatments. Furthermore, data are limited regarding the interplay between radiation- and ICB-induced lung injury, and which biomarkers might be associated with toxicity. Case presentation We report longitudinal clinical and radiologic data, and circulating biomarkers in a melanoma patient treated with axillary radiation followed by ICB who developed consolidation and ground glass opacities (GGO) within the radiation field suggestive of radiation-pneumonitis followed by consolidation outside of the radiation field suggestive of ICB-related pneumonitis. Of note, symptomatic radiation-pneumonitis developed despite a low radiation dose to the lung (V20
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2051-1426
Relation: http://link.springer.com/article/10.1186/s40425-019-0583-3; https://doaj.org/toc/2051-1426
DOI: 10.1186/s40425-019-0583-3
Access URL: https://doaj.org/article/1df37f709046454bb97a314f17915995
Accession Number: edsdoj.1df37f709046454bb97a314f17915995
Database: Directory of Open Access Journals
More Details
ISSN:20511426
DOI:10.1186/s40425-019-0583-3
Published in:Journal for ImmunoTherapy of Cancer
Language:English